Latest Content

Disitamab vedotin demonstrated responses in previously treated HER2-expressing advanced urothelial carcinoma, with activity across HER2 expression levels.

Adding cabazitaxel to hormone therapy and radiation did not improve survival and caused more side effects in high-risk localized prostate cancer.

Padcev plus Keytruda before and after surgery helped more bladder cancer patients live longer and remain cancer-free than standard chemotherapy.

Despite a trend toward more patient-centered research, quality-of-life end points remain substantially underreported in phase 3 genitourinary cancer trials.

Dr. Eric Singer discusses rising early-onset kidney cancer, the role of hereditary syndromes like VHL, and lifestyle tips for patients under age 50.

Adding 177Lu-PSMA-617 to combination therapy improves disease control in PSMA+ mHSPC while maintaining quality of life and pain outcomes.

Dr. Ranee Mehra shares guidance on recurrence, quality-of-life concerns and clinical trials for patients with head and neck cancers and caregivers.

Six years after a colon cancer diagnosis, Carla Deschamps reflects on growth, independence and optimism shaped by survivorship.

CURE highlights prostate cancer advancements from Day One of the 2026 ASCO Genitourinary Cancers Symposium.

CAPItello-281 shows Truqap plus Zytiga extends rPFS in PTEN-deficient mHSPC with manageable toxicity and preserved overall quality of life.

Subcutaneous Rybrevant plus Keytruda led to a 56% response rate in recurrent or metastatic head and neck cancer in OrigAMI-4.

FDA approved Hernexeos for untreated HER2-mutant NSCLC after 76% of patients had tumor shrinkage in clinical trial data.

The landscape of relapsed or refractory multiple myeloma (RRMM) treatment is shifting toward a more targeted future, as Dr. Sagar Lonial explained.